Update advice on the lock procedure for the medicinal product atidarsagene autotemcel (Libmeldy®) for the treatment of metachromatic leukodystrophy (MLD)

The National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) to renegotiate the price of atidarsagene autotemcel (AA; Libmeldy®). This advice is based on insights from newly supplied longer-term data on the effects of the medicinal product. This medicinal product can be used in the treatment of the severe metabolic disease metachromatic leukodystrophy (MLD) in children. Previously, the National Health Care Institute advised that AA should only be reimbursed from the basic health care package after successful price negotiations. This has so far been unsuccessful.